⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL30892889 | 1.00 | CRBN (0.94) | — | |
| Uracil SCHEMBL5089507 | 0.97 | — | — | |
| Uracil SCHEMBL3798527 | 0.97 | CRBN (1.00) | — | |
| Uracil SCHEMBL8235 | 0.97 | — | — | |
| Uracil SCHEMBL16116311 | 0.94 | — | — | |
| Uracil SCHEMBL18010636 | 0.94 | — | — | |
| Uracil SCHEMBL2557975 | 0.94 | — | — | |
| Uracil SCHEMBL4664232 | 0.94 | CRBN (0.94) | — | |
| Uracil SCHEMBL21385227 | 0.94 | — | — | |
| Uracil SCHEMBL8767625 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144792-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ HUMAINES S.E.C. (CA) | 2026-05-28 | — | — | US | claimed |
| US-20250302837-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-10-02 | — | — | US | claimed |
| EP-4504201-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2025-02-12 | — | — | EP | claimed |
| CN-119278042-A | Chymase inhibitors for selective dissolution of thrombi in thrombotic or thromboembolic disorders | 索克普拉健康与人文科学公司 | 2025-01-07 | — | — | CN | claimed |
| WO-2023194222-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ HUMAINES S.E.C. (CA) | 2023-10-12 | — | — | WO | claimed |
| US-11266646-B2 | Use of chymase inhibitors for the treatment of endometriosis, post operative fibrosis and diseases which are characterized by fibrosis formation | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-03-08 | — | — | US | claimed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | claimed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | claimed |
| EP-3558316-A1 | USE OF CHYMASE INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS, POST-OPERATIVE FIBROSIS AND DISEASES WHICH ARE CHARACTERIZED BY FIBROSIS FORMATION | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| US-10407456-B2 | Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof | QUIMICA SINTETICA, S.A. (ES) | 2019-09-10 | — | — | US | claimed |
| US-20170020875-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | claimed |
| US-9481672-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-01 | — | — | US | claimed |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | claimed |
| WO-2016151542-A1 | NUCLEOSIDE PHOSPHORAMIDATES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND PREPARATION THEREOF | QUIMICA SINTETICA, S.A. (ES) | 2016-09-29 | — | — | WO | claimed |
| US-20160244415-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | claimed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | claimed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | claimed |
| CN-100508961-C | Compound medicine of GST activated anticancer compound and another anticancer therapy and pharmaceutical application | TELIK INC (US) | 2009-07-08 | — | — | CN | claimed |
| CN-1711076-A | Combination cancer therapy of a GST-activated anticancer compound and another anticancer therapy | TELIK INC (US) | 2005-12-21 | — | — | CN | claimed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | claimed |